Innate Pharma Sa IPHA Stock Forecast
AI-powered price prediction and analysis for Innate Pharma Sa · Alpha · vs marketSwitch to Total
See IPHA's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Innate Pharma Sa
Innate Pharma Sa (IPHA) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
Where IPHA sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| IPHA Innate Pharma Sa | ▼ | $139M | – |
| AMGN Amgen Inc | ▼ | $234.65B | 27.0x |
| GILD Gilead Sciences, Inc. | ▲ | $195.13B | – |
| MRNA Moderna, Inc. | ▲ | $94.42B | – |
| ARGX Argenx Se | ▼ | $52.37B | 22.2x |
| RVMD Revolution Medicines, Inc. | ▲ | $40.57B | – |
| BIIB Biogen Inc. | ▼ | $34.53B | 25.3x |
| BNTX Biontech Se | ▲ | $22.81B | 2.3x |
| EXEL Exelixis, Inc. | ▶ | $15.57B | 18.1x |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B | 19.8x |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.79B | 27.9x |
| TECH Bio-Techne Corp | ▼ | $11.37B | 62.5x |
| IBRX Immunitybio, Inc. | ▲ | $10.60B | – |
| RGEN Repligen Corp | ▶ | $10.39B | 266.9x |
| QGEN Qiagen N.V. | ▶ | $10.02B | 32.7x |
| KRYS Krystal Biotech, Inc. | ▶ | $9.77B | 41.4x |
| PCVX Vaxcyte, Inc. | ▲ | $9.71B | – |
| TWST Twist Bioscience Corp | ▲ | $9.06B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.67B | – |
| IMVT Immunovant, Inc. | ▲ | $5.68B | – |
| KOD Kodiak Sciences Inc. | ▲ | $5.54B | – |
| CGON Cg Oncology, Inc. | ▲ | $5.48B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.98B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $4.95B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.08B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.79B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.12B | – |
| DNLI Denali Therapeutics Inc. | ▼ | $2.93B | – |
| BEAM Beam Therapeutics Inc. | ▲ | $2.55B | 98.9x |
| LIFE Atyr Pharma Inc | ▲ | $2.45B | – |
| ADMA Adma Biologics, Inc. | ▼ | $2.40B | 17.3x |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.23B | – |
| NVAX Novavax Inc | ▲ | $2.11B | – |
| VCEL Vericel Corp | ▶ | $2.10B | 110.9x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.05B | – |
| ALVO Alvotech | ▲ | $1.90B | – |
| MESO Mesoblast Ltd | ▶ | $1.79B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.77B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B | – |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.52B | – |
| IMCR Immunocore Holdings Plc | ▶ | $1.52B | – |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.22B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.22B | – |
| VOR Vor Biopharma Inc. | ▲ | $1.14B | – |
| REPL Replimune Group, Inc. | ▲ | $1.11B | – |
| JATT Zura Bio Ltd | ▶ | $994M | – |
| VALN Valneva Se | ▼ | $965M | – |
| IMTX Immatics N.V. | ▲ | $957M | – |
| MGTX Meiragtx Holdings Plc | ▼ | $950M | 12.8x |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $901M | – |
| SLBT Sl Science Holding Ltd | ▶ | $884M | – |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $863M | – |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $844M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M | – |
| SANA Sana Biotechnology, Inc. | ▲ | $741M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $711M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $682M | – |
| AURA Aura Biosciences, Inc. | ▲ | $657M | – |
| PRME Prime Medicine, Inc. | ▲ | $655M | – |
FAQ
Is Innate Pharma Sa a good stock to buy?
Our AI analyzes Innate Pharma Sa daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Innate Pharma Sa predictions?
For IPHA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 13.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Innate Pharma Sa forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Innate Pharma Sa? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.